Clinical trials
Sexually Transmitted Infections (Not HIV or Hepatitis) clinical trials
Below are recruiting sexually transmitted infections (not hiv or hepatitis) clinical trials, each written for real people, not researchers. We’re tracking 794 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06962332RecruitingPhase 1
Study of Zanzalintinib in People with Moderate Liver Problems
This trial looks at how a drug called Zanzalintinib acts in people with moderate liver impairment compared to healthy volunteers. It aims to ensure the drug is safe and at the right dose for people with liver issues.
Orlando, FloridaAges 18–75 - NCT07044297RecruitingPhase 3
A study of a new long-acting shot to prevent HIV
This study tests an investigational long-acting shot (MK-8527) to prevent HIV. It is for HIV-negative people who are at higher risk through anal sex without condoms, and who have not used other long-acting HIV prevention before.
Birmingham, AlabamaAges 16 years+ - NCT07071623RecruitingPhase 3
A study of an experimental drug to prevent HIV
This trial tests a new medication called MK-8527 to see if it can prevent HIV-1 infection in women who are at risk. If you are a cisgender woman, HIV-negative, and sexually active, this study could be an option for you.
Homabay County, Homa Bay CountyAges 16–30 - NCT07248839RecruitingPhase 1
Drug levels and safety for people with different liver function
This trial tests how a drug (BMS-986435) behaves in people with normal liver function versus those with liver problems. It also checks that the drug is safe for the heart.
Chandler, ArizonaAges 18–75 - NCT07250633RecruitingPhase 1
Study of Vorasidenib in severe liver disease and healthy volunteers
This trial tests how the drug vorasidenib behaves in people with severe liver problems compared to healthy volunteers. It helps doctors understand if the drug needs different dosing for patients with liver disease.
Chandler, ArizonaAges 18–75 - NCT00001971Recruiting
Evaluation of patients with liver disease
This research study evaluates people with liver disease or at risk for liver disease, and compares them with healthy volunteers. The goal is to better understand liver disease and improve how doctors diagnose and treat it.
Bethesda, MarylandAges 2–100 - NCT03146884Recruiting
Study of autoimmune hepatitis in people living in Switzerland
This study looks at people with autoimmune hepatitis (an immune system condition that attacks the liver). It aims to learn more about the disease by following patients who live in Switzerland.
Lugano, Canton TicinoAges Any age - NCT07424963Recruiting
Comparing two ways to measure liver pressure
This study compares a newer, less invasive method using an endoscope (EUS-PPG) with a standard catheter method (HVPG) to measure liver pressure in people with advanced liver disease. The goal is to see if the newer method is equally accurate and safer.
Prague, BohemiaAges 18–75 - NCT07491848Recruiting
Mouth health study for hepatitis B and D patients
This study looks at mouth health in people with hepatitis B and D, including those taking a medicine called bulevirtide and those not taking it. It may help understand how these infections affect the mouth and gums.
CraiovaAges 18 years+ - NCT07226128Recruiting
Can therapy help HIV patients with depression and insulin resistance?
This study tests if cognitive behavioral therapy (a type of talk therapy) can improve how your body handles sugar (insulin resistance) for people living with HIV who also have depression. You may join if you have HIV, are on stable HIV meds, feel depressed, and do not have diabetes.
Indianapolis, IndianaAges 18 years+ - NCT07677358RecruitingPhase 1
Atirmociclib in people with normal or reduced liver function
This study tests how the body handles the medicine Atirmociclib in people with different levels of liver function, from normal to moderate or severe liver disease. It helps doctors understand if the dose needs to be adjusted for people with liver problems.
Miami Lakes, FloridaAges 18 years+ - NCT07422610RecruitingPhase 1
Study of Pelabresib for advanced cancer with liver issues
This trial tests how the drug pelabresib works in people with advanced cancer who also have mild to severe liver problems. It aims to understand safety and how the drug moves through the body.
BordeauxAges 18–75 - NCT07314905RecruitingPhase 3
Treatments for respiratory infections in community settings
This study is testing different treatments for people with respiratory infections like the flu who are not in the hospital. You may be able to join if you have a positive test, have symptoms like cough or fever, and start within a few days of feeling sick.
Toronto, OntarioAges 18 years+ - NCT07146100Recruiting
Long-term follow-up after AHB-137 treatment for hepatitis B
This study follows participants with chronic hepatitis B who previously responded to the drug AHB-137. The goal is to track long-term health and safety after their treatment.
Hefei, AnhuiAges 18 years+ - NCT06925321RecruitingPhase 3
Testing Fosmanogepix for Serious Mold Infections
This trial tests a new drug, Fosmanogepix, for treating serious mold infections that are hard to treat with current medicines. It may be an option for people with limited treatment choices.
Birmingham, AlabamaAges 18 years+ - NCT06680232RecruitingPhase 1
Gene therapy trial for chronic hepatitis B
This trial tests a gene therapy called PBGENE-HBV for people with chronic hepatitis B who are already on antiviral treatment. The goal is to see if it is safe and can help control the virus.
Boston, MassachusettsAges 18–70 - NCT05419024RecruitingPhase 2
Imaging and biopsy during a planned HIV treatment pause
This Phase 2 study uses special scans (PET/CT) and tissue sampling (biopsy) to learn what is happening in the body while people with HIV take a planned break from antiretroviral therapy (ART) for up to 90 days. It may help researchers find better ways to control HIV without ongoing treatment, though joining involves careful monitoring during the pause.
Bethesda, MarylandAges 18–100 - NCT07216794RecruitingPhase 2
Alendronate trial to reduce hidden HIV
This study tests if alendronate, a bone-strengthening medicine, can shrink the reservoir of HIV that stays in your body even when on treatment. You must have well-controlled HIV on antiretroviral therapy for at least one year but no more than ten years, and meet specific health requirements.
San Francisco, CaliforniaAges 18–65 - NCT07220915RecruitingPhase 3
Study of Panzyga to prevent infections in people with weak immune systems
This trial tests if a medication called Panzyga can help prevent infections in people with autoimmune conditions who have low antibody levels after B-cell therapy. It may be an option if you have a condition like multiple sclerosis, rheumatoid arthritis, or lupus.
Scottsdale, ArizonaAges 18 years+ - NCT06993454Recruiting
Exercise and blood sugar in type 2 diabetes with fatty liver
This study looks at how a single session of exercise affects the body's natural sugar production in people with type 2 diabetes and fatty liver. It may help us find better ways to control blood sugar and treat fatty liver.
Orlando, FloridaAges 25–55 - NCT05592626RecruitingPhase 1/Phase 2
T cell activator STAR0602 for advanced solid tumors
This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.
Sacramento, CaliforniaAges 18 years+ - NCT07270809Recruiting
Chronic liver disease with organ failure: early outcomes study
This study follows patients with chronic liver disease who are hospitalized non-electively for organ failure, to understand the course of illness and outcomes over six months. It may help doctors improve care for similar patients.
New Delhi, National Capital Territory of DelhiAges 18–70 - NCT06775496Recruiting
Study of life-threatening infections to find genetic causes
This trial studies people who have had a life-threatening infection to look for genetic reasons why some infections are so severe. If you or a child had a serious infection—like severe flu, meningitis, or a deep abscess—that could not be explained by a weak immune system from other causes, this study may help find answers.
Bologna, BolognaAges Any age - NCT05484206RecruitingPhase 1
Study how liver impairment affects two investigational medicines
This Phase 1 study tests how two investigational medicines move through the body and how safe they are in people with different levels of liver impairment, compared with healthy volunteers. It may help doctors understand dosing and safety for people with liver problems.
Rialto, CaliforniaAges 18–70
Hear when a new Sexually Transmitted Infections (Not HIV or Hepatitis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for sexually transmitted infections (not hiv or hepatitis)?
- Yes. Clin2 currently lists 794 recruiting sexually transmitted infections (not hiv or hepatitis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sexually transmitted infections (not hiv or hepatitis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sexually transmitted infections (not hiv or hepatitis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.